Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.44 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20643697 | 0.91 | DNM1 (0.47) | DNM1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL13363959 | 0.82 | DNM1 (0.54) | DNM1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL10657930 | 0.80 | NOD1 (0.55) | MEN1FAAHMAPK1KMT2ALPAR3 | |
| SCHEMBL10657934 | 0.80 | NOD1 (0.55) | MEN1FAAHMAPK1KMT2ALPAR3 | |
| SCHEMBL25594538 | 0.79 | CYP2C9 (0.45) | DNM1MEN1KMT2APLA2G2C | |
| SCHEMBL22183458 | 0.79 | CNR2 (0.40) | DNM1PLA2G2CCNR1CNR2 | |
| SCHEMBL20803682 | 0.78 | FAAH (0.55) | DNM1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL26508154 | 0.78 | LPAR3 (0.59) | FAAHLPAR3PLA2G4ACNR1CNR2 | |
| SCHEMBL19142525 | 0.78 | DNM1 (0.56) | DNM1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL22247594 | 0.77 | MEN1 (0.44) | DNM1MEN1KMT2APLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10982007-B2 | Detection of a posttranslationally modified polypeptide by a bivalent binding agent | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200277406-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2020-09-03 | — | — | US | disclosed |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10633460-B2 | Binding agent | ROCHE DIAGNOSTIC OPERATIONS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-2659275-B1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2036897-B1 | Stable rhodamine labeling reagent | ROCHE DIAGNOSTICS GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| EP-2867255-B1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| US-20160194410-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20150232560-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289251-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| WO-2012085111-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085113-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085064-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085069-A2 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| EP-2036897-A1 | Stable rhodamine labeling reagent | Roche Diagnostics GmbH (DE) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289251-A1 | BINDING AGENT | SSB, APBA1, SHBG | DNM1 2490/4885MEN1 2471/4885FAAH 3370/4885 |
| US-20150232560-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | FCGR3B, VSIG8, CD47 | DNM1 647/4885MEN1 1717/4885FAAH 4349/4885 |
| US-10982007-B2 | Detection of a posttranslationally modified polypeptide by a bivalent binding agent | PTMS, CD2BP2, PSMA2 | DNM1 2211/4885MEN1 2130/4885FAAH 4058/4885 |
| US-20160194410-A1 | BINDING AGENT | SSB, APBA1, SHBG | DNM1 2451/4885MEN1 2482/4885FAAH 3377/4885 |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | PTMS, CD2BP2, PSMA2 | DNM1 2211/4885MEN1 2130/4885FAAH 4058/4885 |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | PTMS, DNPEP, CD2BP2 | DNM1 1705/4885MEN1 2004/4885FAAH 4046/4885 |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | PNKP, RNASE1, DCLRE1B | DNM1 2157/4885MEN1 2817/4885FAAH 4529/4885 |
| US-10633460-B2 | Binding agent | SSB, APBA1, SHBG | DNM1 2451/4885MEN1 2482/4885FAAH 3377/4885 |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | PA2G4, BRDT, CD2BP2 | DNM1 1159/4885MEN1 1140/4885FAAH 4140/4885 |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | PA2G4, BRDT, CD2BP2 | DNM1 1159/4885MEN1 1140/4885FAAH 4140/4885 |
| US-20200277406-A1 | BINDING AGENT | SSB, APBA1, SHBG | DNM1 2451/4885MEN1 2482/4885FAAH 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.